A20 (ATCC® TIB-208TM) is a murine lymphoma cell line derived from a spontaneous reticulum cell neoplasm of a Balb/c mouse.
*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.
A20 cells are suitable for in vitro and in vivo experimentation. The cells will form tumors and spontaneous metastases in immunocompromised and syngeneic Balb/c mice. Depending on the route of inoculation (see below), implanted A20 cells can metastasize to numerous sites including the bone marrow, liver, spleen, lymph nodes, ovaries, and peritoneal cavity.
The following chart provides some examples of A20 cells used for tumor formation and studies.
|Route of Implantation||Mice||Tumor/Metastases||References|
|Subcutaneous||Balb/c||Subcutaneous tumor, liver and lymph node metastases|
|Bone marrow, spinal cord|
|Intracranial||Balb/c||Brain tumors and metastases|
|Intravenous||Balb/c||Liver, ovaries, lymph nodes, bone marrow, spleen, peritoneal cavity||
Wen et al. (2010) Lab Animal Res 26: 415-423.
Stable reporter cell lines:
Our A20 reporter cells expressing firefly luciferase (Fluc) can be tracked in vivo, making them great tools for studying the mechanisms of tumor growth and metastasis, as well as evaluating the effects of various drugs or therapies in animals.
In order to ensure high, constitutive expression of the reporter proteins, our cell lines are generated by lentiviral vector transduction. The lentiviral vectors used for these transductions are self-inactivating (SIN) vectors in which the viral enhancer and promoter has been deleted. This increases the biosafety of the lentiviral vectors by preventing mobilization of replication competent viruses (Miyoshi et al., J Virol. 1998).